Is AUPH or AVBP more undervalued in 2026?

CirclFi compares Aurinia Pharmaceuticals Inc (AUPH) and ArriVent BioPharma, Inc. (AVBP) using 13 institutional-grade valuation models. AUPH has a Quality of Company score of 9.9/10 while AVBP scores 3.6/10.

Which is a better buy — AUPH or AVBP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AUPH and AVBP valuations compare?

AUPH at $15.35 and AVBP at $26.97 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AUPH vs AVBP Valuation Comparison 2026 — Intrinsic Value Analysis

AUPH

Biotechnology

Aurinia Pharmaceuticals Inc

Quality

9.9

out of 10

Value Trap

SAFE

Price

$15.35

Last close

Models

13/13

Active

AVBP

Biotechnology

ArriVent BioPharma, Inc.

Quality

3.6

out of 10

Value Trap

SAFE

Price

$26.97

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	AUPH Fair Value	AUPH Upside	AVBP Fair Value	AVBP Upside
Bayesian DCF	Intrinsic	$15.99	+4.1%	$7.90	-70.7%
Earnings Power Value	Intrinsic	$6.74	-56.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.86	-87.9%	$6.38	-76.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AUPH vs AVBP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AUPH vs AVBP — Which Stock Is More Undervalued?

AUPH scores higher with a 9.9/10 quality rating vs AVBP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aurinia Pharmaceuticals Inc (AUPH) and ArriVent BioPharma, Inc. (AVBP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AUPH currently trades at $15.35 with a QOC of 9.9/10, while AVBP trades at $26.97 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).